COMMUNIQUÉS West-GlobeNewswire

CalMHSA Selects Eleos as Statewide AI Technology Partner for Behavioral Health
11/02/2026
Eleos’ AI platform pairs with Streamline Healthcare Solutions’ EHR in counties across California, supporting enhanced human connection in behavioral health care delivery BOSTON and OAK BROOK, Ill. and SACRAMENTO, Calif [...]
LeMaitre Will Announce Fourth Quarter 2025 Earnings Results February 25, 2026
11/02/2026
BURLINGTON, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its fourth quarter 2025 financial results on Wednesday, February 25, 2026, after the market [...]
HepaRegeniX Completes Phase Ib Study of HRX-215 to Enhance Liver Regeneration in Patients Undergoing Minor Liver Resection
11/02/2026
Tuebingen, Germany, February 11, 2026 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage biotech company advancing novel therapies for acute and chronic liver diseases, today announced the completion of the Phase Ib [...]
Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs
11/02/2026
Company advances its leadership in MASH with an expanded pipeline, which now includes more than 10 programs at multiple stages of development, anchored by Rezdiffra ® (resmetirom) as the foundational treatment Madrigal [...]
Secura Bio Expands Chief Financial Officer Will Brown’s Leadership Role to Include Chief Operating Officer
11/02/2026
BERKELEY HEIGHTS, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Secura Bio, Inc. ( www.securabio.com ), an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced that Will [...]
Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma
11/02/2026
– Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing – – Verekitug also delivered clinically [...]
PL BioScience Wins Regulatory Certification from Japan’s PMDA
11/02/2026
Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) has issued a Material Qualification Certificate for ELAREM™ Ultimate-FD PLUS (GMP Grade) cell culture media. The PMDA Certification is the first regulatory [...]
Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress
11/02/2026
-- Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide in older patients with obesity on track to initiate this quarter— --Company to host conference call and webcast today at 8:00 a.m. [...]
AscellaHealth Expands International Operations, Broadens Executive Leadership to Accelerate Global Market Access for Life Sciences
11/02/2026
DUBLIN and BERWYN, Pa., Feb. 11, 2026 (GLOBE NEWSWIRE) -- AscellaHealth , a global partner delivering customizable solutions to support the specialty pharmaceutical industry, today announces expanded leadership roles [...]
Rentschler Biopharma appoints Dr. Veit Bergendahl as Chief Operating Officer and member of the executive board
11/02/2026
Dr. Bergendahl will assume operational responsibility for process development, clinical and commercial cGMP manufacturing, engineering and technology, and production automation, effective April 1, 2026 Industry expert [...]
Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets
11/02/2026
Tempest outlines a capital-efficient post-transaction strategy to advance a diversified portfolio of next-generation CAR-T and oncology assets Development approach prioritizes partner-funded and externally supported [...]
NTG Nordic Transport Group A/S - 2025 Annual Report Conference Call
11/02/2026
NTG Nordic Transport Group A/S – 2025 Annual Report Conference Call We expect to release the 2025 Annual Report of NTG Nordic Transport Group on the evening of March 4, 2026. A webcast and conference call will be held [...]
SEISMIC consortium secures EUR 23.5 million IHI grant to pioneer next-generation minimally invasive brain treatments
11/02/2026
February 11, 2026 Co-funded by the EU’s Innovative Health Initiative (IHI), the research consortium is coordinated by Philips, together with Erasmus MC as academic lead, and will combine advanced medical imaging and [...]
Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran
11/02/2026
BOSTON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Bioxytran, Inc. ( OTCQB: BIXT ) today announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization [...]
Helsinn and MagnaPharm enter long-term agreement for AKYNZEO® and ALOXI® across five Central and Eastern European countries
11/02/2026
Lugano, Switzerland – February 11th, 2026 – Helsinn Healthcare SA (“Helsinn”), a global pharmaceutical group focused on supporting patients with cancer and chronic diseases, and MagnaPharm, a leading pharmaceutical [...]
Reset Health Further Strengthens Advisory Board With Appointment of Pinder Sahota
11/02/2026
The appointment of former General Manager of Novo Nordisk UK follows the recent appointment of Professor Sir Jonathan Van-Tam to Reset Health’s Advisory Board LONDON, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Reset Health (“the [...]
InfiniHealth Medical Group Announces Integrated Multispecialty Care Model to Support Coordinated Specialty Services Across New Jersey
11/02/2026
WEST ORANGE, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- InfiniHealth Medical Group today announced the continued advancement of its integrated multispecialty care model, a clinical framework that brings multiple board- [...]
Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial
11/02/2026
Global CRO to support execution of ZIMA-101 study with world's first MAGE-A4-targeting TCR-NK cell therapy product Partnership follows submission of the Clinical Trial Application (CTA) to the MHRA Oslo, Norway – 11 [...]
Galecto Announces Pricing of $275 Million Underwritten Public Offering
11/02/2026
BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today [...]

Pages